Edwards Lifesciences Corp SEC Filings

Edwards Lifesciences Corp ownership disclosure: Vanguard Capital Management reports beneficial ownership of 43,477,533 shares of Common Stock, representing 7.54% of the class as reported. The filing shows 5,749,741 shares with sole voting power and 43,477,533 shares with sole dispositive power. The statement attributes holdings to Vanguard-related entities and is signed by a Vanguard official.

Edwards Lifesciences reported strong first quarter 2026 results, with net sales of $1.65 billion, up 16.7% year over year, and constant currency sales growth of 12.7%. GAAP diluted EPS was $0.66 and adjusted EPS was $0.78, reflecting solid operational performance.

TAVR sales rose 14.4% to $1.20 billion and TMTT sales reached $173 million, both supported by broader adoption of SAPIEN, EVOQUE, PASCAL and SAPIEN M3 therapies. Surgical sales grew 10.1% to $276 million, driven by RESILIA-based products and new launches.

The company raised its 2026 constant currency sales growth guidance to 9%–11%, TAVR growth guidance to 7%–9%, and adjusted EPS guidance to $2.95–$3.05. Gross margin remained high at 78.0% (78.2% adjusted). Edwards ended the quarter with about $2.4 billion in cash, $600 million of total debt, and completed a $500 million accelerated share repurchase.

Edwards Lifesciences CVP and Chief Financial Officer Scott B. Ullem exercised employee stock options for 13,000 shares of common stock at an exercise price of $59.2567 per share and sold 13,000 shares in open-market transactions. The sales occurred in two tranches at weighted average prices of $80.4963 and $79.7866 per share under a pre-arranged Rule 10b5-1 trading plan adopted on July 29, 2025. After these transactions, he holds 39,699 shares directly and 266,318 shares indirectly through a trust, resulting in a net reduction of 13,000 shares in his position.

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, exercised employee stock options for 1,019 shares of common stock at an exercise price of $59.2567 per share and immediately sold 1,019 shares at a weighted average price of $80.9840 per share.

These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 30, 2025, indicating they were scheduled in advance. Following the transactions, Lippis directly owns 33,933.9103 shares of Edwards Lifesciences common stock.

Edwards Lifesciences Corp corporate VP Donald E. Bobo Jr. exercised employee stock options for 22,680 shares of common stock at an exercise price of $59.2567 per share. On the same date, he sold a total of 22,680 shares in open-market transactions at weighted average prices of $80.5915 and $80.0494 per share.

After these transactions, he directly holds 21,266.2532 shares of common stock, with additional indirect holdings of shares represented in a 401(k) plan and a trust. The filing states that these trades were effected under a Rule 10b5-1 trading plan adopted on February 27, 2025.

Edwards Lifesciences Corp ownership update: The Vanguard Group filed an amendment reporting 0 shares beneficially owned and 0% of common stock as of the amendment. The filing explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries to report separately.

Edwards Lifesciences reported strong 2025 results and strategic progress across structural heart therapies. Net sales from continuing operations were $6.1B with an adjusted net sales growth rate of 10.7%. The company invested more than $1B in research and development (about 17.8% of sales) and reported a gross margin of 78%. Product milestones included regulatory approvals and evidence gains for the SAPIEN family (including an approval for asymptomatic severe aortic stenosis), U.S. and EU approvals for SAPIEN M3, favorable real-world registry outcomes for EVOQUE, and long-term durability data for RESILIA. Edwards employed ~16,000 people and reported 580.8 million shares outstanding as of January 31, 2026. The report describes forward-looking plans for expanded adoption, clinical evidence generation, and continued investment in emerging areas such as heart failure and aortic regurgitation, and includes standard forward-looking statement cautions.

Edwards Lifesciences Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on May 7, 2026. Holders of common stock as of March 10, 2026 can vote online, by phone, mail, or during the webcast.

Stockholders will elect nine directors for one-year terms, cast an advisory vote on named executive officer pay, ratify PricewaterhouseCoopers LLP as independent auditor for 2026, and approve an amended and restated Long-Term Stock Incentive Compensation Program. The board, led by an independent chair, recommends voting “FOR” all four proposals.

The company highlights 2025 sales of $6.1 billion, up 11.5% on an underlying basis, and more than $1 billion invested in research and development across TAVR, TMTT and Surgical therapies. Annual cash incentives funded at 127% of target, while 2022 performance-based RSUs tied to three-year relative total shareholder return did not vest. Edwards emphasizes strong governance features, including majority voting for directors, proxy access, no poison pill, robust stock ownership guidelines and an executive pay program where a high proportion of compensation is performance-based.

Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem exercised options for 13,000 shares of common stock at $59.2567 per share on March 11, 2026, then sold all 13,000 shares in open-market transactions at weighted average prices of $84.4613 and $85.2079.

After these transactions, he holds 39,699 shares directly and 266,318 shares indirectly through a trust, so the 13,000-share sale represents a small portion of his total reported holdings. All transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 29, 2025, indicating they were scheduled in advance.